



Living Cell Technologies Limited

(the "Company")
Registered Office
Level 7
330 Collins Street
MELBOURNE VIC 3000

ASX Code: LCT

19 October 2018

Mr George Tharian
Advisor
Australian Securities Exchange
20 Bridge Street
SYDNEY NSW 2000

Dear Mr Tharian,

Thank you for your letter dated 19 October 2018. The response to the questions that you ask in your letter are as follows (your numbers referenced below):

1. The Company is not aware of any information concerning it that has not been announced which, if known could be an explanation for recent trading in the securities of the Company.
2. Not applicable.
3. There is no other explanation that the Company has for the recent trading in the securities of the Company.
4. I confirm that the Company is in compliance with ASX Listing Rules and in particular Listing Rule 3.1. The Company further advises that 18 month efficacy data for NTCELL for Parkinson's disease will not become available until November 2018. The results of which may determine progress towards product commercialisation and will be released to the market immediately they are confirmed.
5. I confirm that the responses to the questions have been authorised and approved in accordance with the Company's Communication and Disclosure Policy.

We confirm that this response may be released to the market.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Mark Licciardo', is written over a light grey, stylized signature line that extends to the right.

Mark Licciardo
Company Secretary